Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesJanux Therapeutics Inc

Janux Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
12.37 USD -0.39 ( 3.06%)
Last update at 2026-11-10T14:59:00Z
VOLUME
343996
Market Cap
2352.47M

Momentum Score

…

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
12.21
Low
12.76
High
52 Week Price Range
5.65
Low
65.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Janux Therapeutics is a clinical-stage biotechnology company developing tumor-targeted cytokine immunotherapies using a proprietary delivery platform designed to concentrate immunostimulatory cytokines in the tumor microenvironment to enhance local activity and limit systemic exposure. Long-term growth drivers include clinical development progress, potential to improve the therapeutic index of cytokine treatments in oncology, and successful regulatory or partnership outcomes. The company could appeal to investors seeking exposure to a differentiated approach in cancer immunotherapy with the possibility of addressing unmet needs in solid tumors.
Key risks include significant clinical and regulatory uncertainty, high cash burn with likely future financing and dilution, and strong competition in oncology therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
12.76
Dividend Yield
-
Revenue TTM
7.29M
Revenue Per Share
0.16
Gross Profit TTM
-44.83M
Debt / Equity
0.07
ROE
-11.50%
Net Debt
5.34M
ROCE
-18.49%
Diluted EPS TTM
-1.20

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -63.06M -32.67M -6.78M -4.00M
Net income -54.15M -32.56M -5.25M -4.24M
Selling general administrative 22.26M 10.33M 1.80M 0.77M
Gross profit 8.61M 3.64M - -
Reconciled depreciation 0.84M 0.11M 0.01M 0.01M
Ebit -67.93M -33.04M -4.84M -3.77M
Ebitda -67.09M -32.93M -6.57M -3.77M
Depreciation and amortization 0.84M 0.11M -1.72M 0.01M
Non operating income net other 4.03M 0.26M - -
Operating income -67.09M -32.93M -4.84M -3.77M
Other operating expenses 75.70M 36.57M 4.84M 3.77M
Interest expense 4.03M 0.37M 0.21M 0.23M
Interest income 4.03M 0.26M - -
Net interest income 4.03M 0.26M -0.21M -0.23M
Income tax expense -8.90M -0.11M -1.53M 0.23M
Total revenue 8.61M 3.64M 0.00M 0.00M
Total operating expenses 75.70M 36.57M 4.84M 3.77M
Cost of revenue 75.70M 36.57M - -
Total other income expense net 4.03M 0.26M -1.94M -0.23M
Net income from continuing ops -63.06M -32.67M -6.78M -4.00M
Net income applicable to common shares -63.06M -32.67M -6.78M -4.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 380.41M 364.01M 379.82M 16.22M 0.68M
Other current assets 5.21M 5.42M 2.05M 0.25M -
Total liab 36.06M 43.27M 13.50M 30.86M 8.62M
Total stockholder equity 344.35M 320.74M 366.33M -14.64M -7.94M
Other current liab 7.39M 8.18M 4.98M 0.05M 0.36M
Common stock 0.05M 0.04M 0.04M 0.00M 0.00M
Capital stock 0.05M 0.04M 0.04M 0.00M 0.00M
Retained earnings -168.76M -110.47M -47.41M -14.74M -7.96M
Other liab - 2.22M 0.70M 6.05M -
Other assets - 2.21M 1.21M - -
Cash 19.20M 51.43M 35.58M 7.81M 0.66M
Total current liabilities 13.03M 16.51M 12.80M 3.18M 4.63M
Current deferred revenue 1.71M 5.41M 5.16M 1.95M -
Net debt 5.34M -26.12M -35.39M -7.81M 3.34M
Short term debt 1.52M 0.76M 0.19M 0.75M 4.00M
Short long term debt - - - - 4.00M
Short long term debt total 24.54M 25.30M 0.19M - 4.00M
Other stockholder equity 512.40M 432.70M 34.14M 0.10M 0.01M
Property plant equipment - 7.09M 1.60M 0.15M 0.02M
Total current assets 349.24M 332.44M 377.02M 16.06M 0.66M
Net tangible assets - 320.74M 366.33M -14.64M -7.94M
Short term investments 324.82M 275.59M 339.38M - -
Net receivables 2.20M 0.70M 0.20M 8.00M 0.00M
Inventory -2.20M - - - -
Accounts payable 2.42M 2.16M 2.46M 0.43M 0.27M
Accumulated other comprehensive income 0.67M -1.53M -0.27M - -
Common stock total equity - 0.04M 0.04M 0.00M 0.00M
Retained earnings total equity - -110.47M -47.41M - -
Non currrent assets other 3.33M 2.21M 1.21M - -
Non current assets total 31.17M 31.57M 2.81M 0.15M 0.02M
Capital lease obligations 24.54M 25.30M 0.19M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 64.71M -339.48M -339.48M -339.48M
Change to liabilities 5.63M 0.00M 8.01M 0.00M
Total cashflows from investing activities 58.27M -340.96M -340.96M -340.96M
Net borrowings 23.42M 180.55M 2.50M 4.00M
Total cash from financing activities 0.50M 386.52M 11.52M 4.00M
Change to operating activities 2.81M 0.84M 0.38M -0.07M
Net income -63.06M -32.67M -6.78M -4.00M
Change in cash 15.84M 28.59M 7.16M 0.17M
Begin period cash flow 36.40M 7.81M 0.66M 0.49M
End period cash flow 52.24M 36.40M 7.81M 0.66M
Total cash from operating activities -42.92M -16.98M -4.37M -3.83M
Issuance of capital stock 0.00M 384.71M 8.95M 0.00M
Depreciation 0.84M 0.11M 0.01M 0.01M
Change to inventory - 0.83M 0.38M -
Change to account receivables 0.00M 8.00M -8.00M -8.00M
Sale purchase of stock - 204.17M - -
Other cashflows from financing activities 58.27M 182.36M 11.52M 4.00M
Change to netincome 17.20M 6.74M 2.01M 0.24M
Capital expenditures 6.45M 1.48M 1.48M 1.48M
Change receivables - 8.00M - -
Cash flows other operating -1.35M -2.19M - -
Cash and cash equivalents changes 15.84M 28.59M - -
Change in working capital 4.28M 8.84M 0.39M -0.07M
Stock based compensation 17.20M 6.91M 0.07M 0.01M
Other non cash items -2.18M -0.17M 1.94M 0.23M
Free cash flow -49.37M -18.46M -4.37M -3.83M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
JANX
Janux Therapeutics Inc		 -0.39
3.06%		 12.37 - - 336.50 7.90 296.97 -33.80
NVO
Novo Nordisk A/S		 -0.70
1.70%		 40.67 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.79
0.14%		 550.08 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -6.17
0.67%		 913.79 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Janux Therapeutics Inc

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130

858-751-4493

https://www.januxrx.com

68

Name Title Year Born
Dr. David Alan Campbell Ph.D. Pres, CEO & Director 1960
Dr. Wayne Godfrey M.D. Chief Medical Officer 1961
Mr. Tighe M. Reardon C.F.A., CPA, CPA Acting Chief Financial Officer 1976
Mr. Tommy Diraimondo Ph.D. Sr. Director of Research NA
Ms. Brenda Van Vreeswyk Head of HR NA
Mr. Andy Hollman Meyer Chief Bus. Officer 1984
Mr. Charles M. Winter Sr. VP of Chemistry, Manufacturing & Controls NA
Mr. Byron Robinson J.D., Ph.D. Chief Strategy Officer 1965
Dr. David Alan Campbell Ph.D. President, CEO & Director 1960
Mr. Tighe M. Reardon C.F.A., CPA Acting Chief Financial Officer 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

QTWO
CAD 1.78
+10.56%
NEO
CAD 27.77
+5.91%
CGI
CAD 52.81
+4.78%
PET
CAD 22.34
+3.81%
QBR-A
CAD 77.96
+2.40%
GFL
CAD 57.98
-10.54%
MUX
CAD 21.12
-7.53%
BYN
CAD 1.58
-7.06%
BRVO
CAD 2.23
-6.89%
ITR
CAD 3.12
-6.87%

Equity Sectors*

  • Basic Materials

    -4.26%

  • Communication Services

    +0.36%

  • Consumer Cyclical

    -0.62%

  • Consumer Defensive

    -0.33%

  • Energy

    -0.09%

  • Financial Services

    -0.18%

  • Healthcare

    -1.69%

  • Industrials

    -1.10%

  • Real Estate

    -0.83%

  • Technology

    -0.67%

  • Utilities

    +0.31%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…